Searches for hydroxychloroquine, ivermectin, and remdesivir surged and collapsed in step with news coverage during the COVID-19 pandemic, and a study published this week in the Journal of Medical Internet Research (jmir.org) traced that relationship across four years of American data.
The finding: public interest in these repurposed drugs rose and fell with media attention, sometimes within days, and the mismatch between hype and evidence had real consequences.
Roughly 7% of all Google searches, about 1 billion daily, were health-related in 2019, and 86% of US adults reported getting news from an online source in 2023. Search data and news coverage together form a near real-time map of what patients want and what they fear.
In Plain English: The Clinical Takeaway
- Two of the three drugs studied — hydroxychloroquine and ivermectin — did not work against COVID-19 in properly controlled trials, and regulators advised against their use for it.
- Remdesivir did work, modestly, for hospitalized patients, and remains FDA-approved.
- Public demand for unproven drugs was driven partly by news cycles, not by medical evidence — a pattern worth remembering the next time a “miracle treatment” trends online.
Three Drugs, Three Very Different Outcomes
The trajectory of each drug diverged sharply. Hydroxychloroquine, an antimalarial and antirheumatic drug, received an emergency use authorization from the FDA in March 2020 for hospitalized patients with severe COVID-19. The agency revoked it soon after, when clinical trials showed harmful cardiovascular side effects at the doses being dispensed.
Ivermectin, an antihelminthic, was proposed as an antiviral in early 2020. Randomized controlled trials — studies in which participants are randomly assigned to receive the drug or a placebo — ran between mid-2020 and 2021.
Results were inconsistent and inconclusive, and by 2021 the FDA, the National Institutes of Health, and the World Health Organization all recommended against using it for COVID-19. Demand was strong enough to cause shortages of both human and veterinary formulations, the latter used for livestock deworming.
Remdesivir, an antiviral originally developed to treat hepatitis C, took the opposite path. After multiple clinical trials showed moderately improved outcomes among hospitalized cases, the FDA approved it in October 2020 for people hospitalized with COVID-19.
How the Study Measured a Moving Story
The researchers paired two data sources: Google Trends, which returns a relative index of search interest from 0 to 100, and Media Cloud, an open-source tool tracking news coverage across more than 50,000 outlets. They pulled daily data from January 2019 through December 2022, using 2019 as a prepandemic baseline and stopping when interest in all three terms had stayed low for a sustained period.
The technical work was considerable. Because Google Trends normalizes each query window to its own peak, the team ran 1,377 subwindow queries and 153 four-year queries, then rescaled the daily series onto a common scale — 1,461 daily observations per series. Anomaly detection using seasonal decomposition identified spikes in both search interest and coverage, which the team then matched against known current events.
The study also tested whether the relationship ran both ways. Communication researchers call this the “reflection hypothesis”: media does not only drive public interest, it mirrors it. As people searched for drugs they saw in headlines, news outlets covered the drugs people were already searching for.
Interest Followed Politics and Geography
State-level analysis added a political layer. Because COVID-19 treatments became highly politicized early in the pandemic, the researchers modeled whether each state’s 2020 presidential vote share, rurality, and social vulnerability shaped interest.
They measured social vulnerability with the COVID-19 Community Vulnerability Index, which captures economic, structural, and demographic barriers to health care access. Reduced contact with health care providers has previously been linked to riskier health choices, giving the measure a plausible connection to treatment-seeking behavior.
The team also rated the media outlets driving coverage, pulling bias classifications for the top 10 sources per drug from AllSides and Media Bias/Fact Check, preferring 2021 assessments — ratings taken mid-pandemic, when the coverage itself was live.
Contraindications & When to Consult a Doctor
Hydroxychloroquine at the doses dispensed during the pandemic showed cardiovascular side effects in trials, which is why the FDA withdrew its authorization. Neither drug has regulatory support for COVID-19 treatment.
Public interest in repurposed COVID-19 treatments such as hydroxychloroquine, ivermectin, and remdesivir was shaped by media coverage and by health authorities’ recommendations during the pandemic.
The Takeaway for the Next Emergency
The pandemic showed that demand for unproven treatments does more than waste money. It delayed access to appropriate care, drained pharmacy supply for patients who legitimately needed these drugs, and fostered mistrust in the medical system — a cost at both the individual and population level.
The study’s authors frame the lesson for health and policy communities as situational awareness: knowing how the public obtains medical information during a crisis is the first step to reaching people before misinformation does. Google Trends and Media Cloud, both free to use, are now documented tools for doing exactly that.
References
- Journal of Medical Internet Research — study on search interest in alleged COVID-19 treatments and news media coverage, January 2019–December 2022 (jmir.org)
- US Food and Drug Administration — emergency use authorization and revocation for hydroxychloroquine; approval of remdesivir, October 2020
- US National Institutes of Health — COVID-19 treatment guidelines on ivermectin, 2021
- World Health Organization — recommendation against ivermectin for COVID-19, 2021
- AllSides and Media Bias/Fact Check — media bias ratings used in the study
Consult a qualified health care professional regarding any treatment decisions.